<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacogenomics J</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacogenomics J</journal-id><journal-title-group><journal-title>The Pharmacogenomics Journal</journal-title></journal-title-group><issn pub-type="ppub">1470-269X</issn><issn pub-type="epub">1473-1150</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23856854</article-id><article-id pub-id-type="pmc">4034115</article-id><article-id pub-id-type="pii">tpj201323</article-id><article-id pub-id-type="doi">10.1038/tpj.2013.23</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders</article-title><alt-title alt-title-type="running">Pharmacogenetics of methylphenidate in ASD</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>McCracken</surname><given-names>J T</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Badashova</surname><given-names>K K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Posey</surname><given-names>D J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Aman</surname><given-names>M G</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Scahill</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Tierney</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Arnold</surname><given-names>L E</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Vitiello</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Whelan</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chuang</surname><given-names>S Z</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Davies</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Shah</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>McDougle</surname><given-names>C J</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Nurmi</surname><given-names>E L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label><institution>Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Semel Institute for Neuroscience</institution>, Los Angeles, CA, <country>USA</country></aff><aff id="aff2"><label>2</label><institution>Department of Psychiatry, Indiana University School of Medicine,</institution> Indianapolis, IN, <country>USA</country></aff><aff id="aff3"><label>3</label><institution>Departments of Psychiatry and Psychology, The Nisonger Center UCEDD, Ohio State University</institution>, Columbus, OH, <country>USA</country></aff><aff id="aff4"><label>4</label><institution>Child Study Center, Yale University</institution>, New Haven, CT, <country>USA</country></aff><aff id="aff5"><label>5</label><institution>Department of Psychiatry, Kennedy Krieger Institute, Johns Hopkins University</institution>, Baltimore, MD, <country>USA</country></aff><aff id="aff6"><label>6</label><institution>National Institute of Mental Health, National Institutes of Health</institution>, Bethesda, MD, <country>USA</country></aff><aff id="aff7"><label>7</label><institution>Department of Psychiatry, Columbia University</institution>, New York, NY, <country>USA</country></aff><aff id="aff8"><label>8</label><institution>Department of Psychiatry, Lurie Autism Center, Massachusetts General Hospital</institution>, Boston, MA, <country>USA</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label><institution>Department of Psychiatry and Biobehavioral Sciences, UCLA NPI-Semel Institute</institution>, 760 Westwood Plaza, Los Angeles, CA 90024-1759, <country>USA</country>. E-mail: <email>jmccracken@mednet.ucla.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>06</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>16</day><month>07</month><year>2013</year></pub-date><volume>14</volume><issue>3</issue><fpage>295</fpage><lpage>302</lpage><history><date date-type="received"><day>09</day><month>12</month><year>2012</year></date><date date-type="rev-recd"><day>21</day><month>04</month><year>2013</year></date><date date-type="accepted"><day>26</day><month>04</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Macmillan Publishers Limited</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Macmillan Publishers Limited</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><!--author-paid--><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/">http://creativecommons.org/licenses/by-nc-sa/3.0/</ext-link></license-p></license></permissions><abstract><p>Methylphenidate (MPH) reduces hyperactive-impulsive symptoms common in children with autism spectrum disorders (ASDs), however, response and tolerability varies widely. We hypothesized monoaminergic gene variants may moderate MPH effects in ASD, as in typically developing children with attention-deficit/hyperactivity disorder. Genotype data were available for 64 children with ASD and hyperactivity who were exposed to MPH during a 1-week safety/tolerability lead-in phase and 58 who went on to be randomized to placebo and three doses of MPH during a 4-week blinded, crossover study. Outcome measures included the Clinical Global Impression-Improvement (CGI-I) scale and the Aberrant Behavior Checklist (ABC-hyperactivity index). A total of 14 subjects discontinued the study because of MPH side effects. Subjects were genotyped for variants in <italic>DRD1&#x02013;DRD5</italic>, <italic>ADRA2A</italic>, <italic>SLC6A3</italic>, <italic>SLC6A4</italic>, <italic>MAOA</italic> and <italic>MAOB</italic>, and <italic>COMT</italic>. Forty-nine percent of the sample met positive responder criteria. In this modest but relatively homogeneous sample, significant differences by <italic>DRD1</italic> (<italic>P</italic>=0.006), <italic>ADRA2A</italic> (<italic>P</italic>&#x0003c;0.02), <italic>COMT</italic> (<italic>P</italic>&#x0003c;0.04), <italic>DRD3</italic> (<italic>P</italic>&#x0003c;0.05)<italic>, DRD4</italic> (<italic>P</italic>&#x0003c;0.05)<italic>, SLC6A3</italic> (<italic>P</italic>&#x0003c;0.05) and <italic>SLC6A4</italic> (<italic>P</italic>&#x0003c;0.05) genotypes were found for responders versus non-responders. Variants in <italic>DRD2</italic> (<italic>P</italic>&#x0003c;0.001) and <italic>DRD3</italic> (<italic>P</italic>&#x0003c;0.04) were associated with tolerability in the 14 subjects who discontinued the trial. For this first MPH pharmacogenetic study in children with ASD, multiple monoaminergic gene variants may help explain individual differences in MPH's efficacy and tolerability.</p></abstract><kwd-group><kwd>autism spectrum disorders</kwd><kwd>dopamine</kwd><kwd>genetics</kwd><kwd>hyperactivity</kwd><kwd>methylphenidate</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The autism spectrum disorders (ASDs) are a group of neurodevelopmental disorders including autistic disorder, Asperger's disorder and pervasive developmental disorder, not otherwise specified, which share impairment in social communication. Surveys estimate 1 out of 88 to 160 children as having an ASD.<sup><xref ref-type="bibr" rid="bib1">1</xref></sup> Impairment from ASD varies considerably across its core dimensions, but also from associated maladaptive behaviors, such as symptoms resembling attention-deficit/hyperactivity disorder (ADHD).<sup><xref ref-type="bibr" rid="bib2">2</xref>, <xref ref-type="bibr" rid="bib3">3</xref>, <xref ref-type="bibr" rid="bib4">4</xref></sup> Moderate-to-severe hyperactive-impulsive behaviors overlap in one-third or more individuals with ASD. These behaviors are often targeted by pharmacologic and other treatment efforts,<sup><xref ref-type="bibr" rid="bib5">5</xref>, <xref ref-type="bibr" rid="bib6">6</xref></sup> such as stimulants.</p><p>Despite common use of stimulants for ASD,<sup><xref ref-type="bibr" rid="bib7">7</xref>, <xref ref-type="bibr" rid="bib8">8</xref></sup> variable effects and reduced tolerability was suggested from small early studies,<sup><xref ref-type="bibr" rid="bib9">9</xref>, <xref ref-type="bibr" rid="bib10">10</xref>, <xref ref-type="bibr" rid="bib11">11</xref>, <xref ref-type="bibr" rid="bib12">12</xref></sup> but no moderators of response have been reported. In the largest stimulant trial in ASD, the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network (2005) found methylphenidate (MPH) was superior to placebo in reducing ratings of hyperactivity,<sup><xref ref-type="bibr" rid="bib13">13</xref>, <xref ref-type="bibr" rid="bib14">14</xref></sup> but only half (35/72; 49&#x00025;) were considered clinical responders. In addition, 19&#x00025; of subjects were withdrawn because of adverse effects; variability in optimal dose, adverse events and response was striking.<sup><xref ref-type="bibr" rid="bib15">15</xref></sup></p><p>Variability in response to stimulant treatment is well known in typically developing children,<sup><xref ref-type="bibr" rid="bib16">16</xref></sup> and there is interest in individual genetic variation moderating response in the treatment of ADHD.<sup><xref ref-type="bibr" rid="bib17">17</xref>, <xref ref-type="bibr" rid="bib18">18</xref></sup> However, no reports examining the pharmacogenetics of stimulant response exist for children with ASD. In addition, although a small number of reports have described genetic associations with adverse events and stimulants, none in typical ADHD or subjects with ASD have examined possible genetic associations in those with &#x02018;intolerable' side effects leading to dropout.</p><p>Investigations in typically developing children have suggested that variants in catecholamine-related genes may be associated with MPH response in ADHD.<sup><xref ref-type="bibr" rid="bib17">17</xref></sup> The majority of these examined the variable number tandem repeat (VNTR) polymorphism located in the 3&#x02032; untranslated region of the dopamine transporter gene (<italic>SLC6A3</italic>),<sup><xref ref-type="bibr" rid="bib17">17</xref>, <xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib20">20</xref></sup> the site of MPH action. A meta-analysis has suggested that the nine-repeat variant may confer reduced efficacy;<sup><xref ref-type="bibr" rid="bib21">21</xref></sup> however, recent reports showed enhanced response of 9/9 homozygotes with a dose-dependent effect.<sup><xref ref-type="bibr" rid="bib22">22</xref></sup> Investigations of stimulant response and the 48-base pair (bp) VNTR polymorphism in exon 3 of the dopamine D4 receptor (<italic>DRD4</italic>) gene<sup><xref ref-type="bibr" rid="bib17">17</xref></sup> have been mixed, with greater efficacy seen in subjects with one or two copies of the four-repeat VNTR genotype (<italic>DRD4.4</italic>),<sup><xref ref-type="bibr" rid="bib23">23</xref>, <xref ref-type="bibr" rid="bib24">24</xref>, <xref ref-type="bibr" rid="bib25">25</xref></sup> while others found opposite<sup><xref ref-type="bibr" rid="bib26">26</xref></sup> or no effects.<sup><xref ref-type="bibr" rid="bib27">27</xref>, <xref ref-type="bibr" rid="bib28">28</xref>, <xref ref-type="bibr" rid="bib29">29</xref></sup> Variants such as <italic>DAT1 9/10</italic>, <italic>DRD4.7</italic> and the &#x003b1;-adrenergic receptor 2A (ADRA2A) influence the slope of dose-response relations.<sup><xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib22">22</xref></sup> Few data are available regarding the impact of variation in other dopamine (DA)- receptors <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>DRD3</italic> or <italic>DRD5</italic>. Although data are sparse and conflicting, some reports have associated MPH side effects with variants in <italic>DAT1</italic> and <italic>DRD4</italic> as well.<sup><xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib25">25</xref>, <xref ref-type="bibr" rid="bib30">30</xref></sup></p><p>Awareness of pharmacogenetic interactions of other neurotransmitter genes with psychostimulant action has grown. Variants in <italic>ADRA2A</italic> influence response of inattentive symptoms to MPH.<sup><xref ref-type="bibr" rid="bib22">22</xref>, <xref ref-type="bibr" rid="bib31">31</xref>, <xref ref-type="bibr" rid="bib32">32</xref></sup> Interactions between DA and serotonin (5HT) have also been suggested as integral to MPH's behavioral and locomotor effects.<sup><xref ref-type="bibr" rid="bib33">33</xref></sup> Two studies presented significant moderating effects of the 44-bp insertion&#x02013;deletion polymorphism in the promoter region of the serotonin transporter gene (<italic>SLC6A4</italic>),<sup><xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib34">34</xref></sup> although one report did not detect an effect.<sup><xref ref-type="bibr" rid="bib29">29</xref></sup> Genetic variants in <italic>COMT</italic> also influence basal transmitter availability,<sup><xref ref-type="bibr" rid="bib35">35</xref></sup> working memory<sup><xref ref-type="bibr" rid="bib36">36</xref></sup> and cognitive response to acute stimulant administration.<sup><xref ref-type="bibr" rid="bib37">37</xref></sup> In ADHD, three reports concur that the Val158Met <italic>COMT</italic> variant moderates MPH effects.<sup><xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib38">38</xref>, <xref ref-type="bibr" rid="bib39">39</xref></sup></p><p>Variability in existing ADHD pharmacogenetic studies reflect the heterogeneity in methodology and outcomes. MPH dosing differs, there are few randomized, blinded, placebo-controlled studies, and only four assessed outcomes at multiple doses.<sup><xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib20">20</xref>, <xref ref-type="bibr" rid="bib25">25</xref>, <xref ref-type="bibr" rid="bib31">31</xref></sup></p><p>The purpose of this preliminary investigation was to thoroughly evaluate for the first time in subjects with ASD whether gene variants in candidate loci would be found to associate with the overall clinical response to MPH. Candidates were suggested as moderators by at least two prior pharmacogenetic studies of MPH (<italic>DRD4</italic>, <italic>SLC6A3</italic>, <italic>SLC6A4</italic>, <italic>COMT</italic> and <italic>ADRA2A</italic>), risk genes for ADHD, known targets of MPH action (<italic>DRD1</italic>, <italic>DRD2</italic> and <italic>DRD5</italic>)<sup><xref ref-type="bibr" rid="bib40">40</xref></sup> or associated with psychomotor functioning and impulsivity (<italic>DRD2</italic> and <italic>DRD3</italic>).<sup><xref ref-type="bibr" rid="bib41">41</xref>, <xref ref-type="bibr" rid="bib42">42</xref></sup> We hypothesized that gene variants suggested to exert significant effects on MPH response in typically developing children would also influence effects on response and tolerability in a homogeneous sample of children with ASD. However, we noted the multiple findings suggesting dysregulated DA function in ASD,<sup><xref ref-type="bibr" rid="bib43">43</xref>, <xref ref-type="bibr" rid="bib44">44</xref>, <xref ref-type="bibr" rid="bib45">45</xref></sup> which could alter the relations between gene variants and MPH response and tolerability.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Subjects</title><p>The details of the recruitment and baseline characteristics of the sample have been described previously.<sup><xref ref-type="bibr" rid="bib46">46</xref></sup> Briefly, subjects were recruited at the five centers that formed the RUPP Autism Network funded by the National Institute of Mental Health (NIMH). The study was approved by each local institutional review board and monitored by a central NIMH data and safety monitoring board. Written informed consent was obtained from a parent or guardian, and assent was given by the child when capable.</p><p>To be eligible for the study, subjects from 5 to 14 years were required to meet Diagnostic and Statistical Manual, version-IV criteria for autistic disorder, Asperger's disorder, or PDD-NOS using clinical examination and the Autism Diagnostic Interview-Revised,<sup><xref ref-type="bibr" rid="bib47">47</xref></sup> with diagnoses following Diagnostic and Statistical Manual, version-IV criteria. All subjects had significant symptoms of ADHD (based on the Clinical Global Impression (CGI)-Severity and Swanson, Nolan, and Pelham-IV (SNAP-IV)), were medically healthy, and were not taking any concomitant psychotropic drugs during the treatment phase of the study.</p></sec><sec><title>Study design</title><p>Details of the study's design and rationale were published previously.<sup><xref ref-type="bibr" rid="bib46">46</xref></sup> Briefly, it included a 1-week test dose phase of 1-day placebo, and 2 days each of the low, medium and high MPH doses used in the next phase to determine initial MPH tolerability, followed by a 4-week random-order, placebo-controlled, double-blind crossover phase to assess efficacy, and an 8-week open-label continuation phase for subjects showing a positive response to assess the maintenance of beneficial effects.</p><p>Subjects who were unable to tolerate MPH during the test dose phase as evidenced by a CGI rating of &#x02018;much worse' or &#x02018;very much worse' at a low or medium dose of MPH were excluded before being randomized. Subjects who tolerated all three dose levels of MPH during the test dose phase entered into the 4-week double-blind crossover phase. Each subject received placebo and three different doses of MPH in random order, 1-week each.</p><p>Low, medium and high doses of MPH were assigned based on body weight to approximate 0.125, 0.25 and 0.5&#x02009;mg&#x02009;kg<sup>&#x02013;1</sup> per dose, administered morning and noon, with an additional half-dose given at 1600 hours. Subjects with moderate or greater side effects to the highest dose level of MPH in the test dose phase received the medium dose during 2 weeks of the double-blind, crossover phase. Clinicians, the patient and the caregiver were blind to treatment assignment during the crossover phase.</p><p>Positive response was defined as a rating of &#x02018;much improved' or &#x02018;very much improved' on the CGI completed by the masked study clinician and a significant reduction on the Aberrant Behavior Checklist (ABC)-hyperactivity subscale (defined as a 25&#x00025; reduction by both parent and teacher or a 30&#x00025; reduction by parent or teacher) at any given weekly assessment during the blinded phase, and completion of all weeks of the blinded phase. For the purpose of these responder analyses, subjects who dropped out at any point after entering the double-blind phase (<italic>n</italic>=8) are grouped with non-responders. For the purpose of tolerability analyses, any subject who dropped out in either the test dose or double-blind phase secondary to adverse events formed the intolerant group (<italic>n</italic>=14).</p></sec><sec><title>Genotyping</title><p>Ten candidate genes were selected for typing. A total of 36 variants were genotyped across the 10 loci. Common (&#x0003e;10&#x00025;) locus variability was captured across the dopamine receptor genes <italic>DRD1&#x02013;DRD5</italic>, <italic>ADRA2A</italic>, <italic>MAOA</italic> and <italic>MAOB</italic>, and <italic>SLC6A4</italic>. Several known functional variants were also genotyped, including the Val158Met <italic>COMT</italic> non-synonymous single-nucleotide polymorphism (SNP),<sup><xref ref-type="bibr" rid="bib19">19</xref></sup> and VNTRs in <italic>SLC6A3</italic> (480-bp VNTR in the 3&#x02032; untranslated region),<sup><xref ref-type="bibr" rid="bib17">17</xref></sup>
<italic>DRD4</italic> (exon 3 48-bp VNTR)<sup><xref ref-type="bibr" rid="bib48">48</xref></sup> and <italic>SLC6A4</italic> (44-bp insertion&#x02013;deletion in the promoter region (5-HTTLPR) with modifying SNP (rs25531) and intron 2 VNTR (STin2)).<sup><xref ref-type="bibr" rid="bib49">49</xref></sup> To minimize multiple testing of non-independent genotypes, allele frequencies were computed and genotype classifications defined <italic>a priori</italic> to any outcome analyses.</p><p>The <italic>SLC6A3</italic> VNTR (<italic>DAT1</italic>) was genotyped using published methods and primers.<sup><xref ref-type="bibr" rid="bib50">50</xref></sup> The <italic>DRD4</italic>-exon 3 VNTR was genotyped with the following modified primers: F&#x02014;5'-CTACCCTGCCCGCTCATG-3' R&#x02014;5'-CCGGTGATCTTGGCACGC-3' using previously described methods.<sup><xref ref-type="bibr" rid="bib51">51</xref></sup> The <italic>SLC6A4</italic> promoter region gene-linked polymorphic region (5-HTTPLR) short&#x02013;long variant and intron 2 10/12 VNTR (STin2) were genotyped according to published protocols.<sup><xref ref-type="bibr" rid="bib52">52</xref></sup> For VNTR variants (5-HTTLPR, 5-HTT STin2, <italic>DAT</italic> and <italic>DRD4</italic>), PCR products were electrophoresed in 2&#x00025; gold agarose (BMA, Rockland, ME, USA) gels in 1x TBE and imaged with ethidium bromide under fluorescent Kodak digital camera (Rochester, NY, USA). Alleles were determined by comparison with molecular weight standards and control individuals with previously determined genotypes. Samples were double-scored by two technicians.</p><p>Tag SNPs were selected using Haploview Software<sup><xref ref-type="bibr" rid="bib53">53</xref></sup> publicly available from the HapMap Consortium to capture variability present at &#x02a7e;10&#x00025; with an <italic>r</italic><sup>2</sup>&#x02a7e;0.8. SNPs were genotyped using the Life Technologies (Life Technologies, Grand Island, NY, USA) TaqMan platform with Qiagen Type-it Fast SNP Probe PCR Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocols. All genotypes were in Hardy&#x02013;Weinberg Equilibrium (<italic>P</italic>&#x0003e;0.05). Ten percent of the data set was genotyped in duplicate without any conflicting genotypes, and allele frequencies were checked for consistency with those reported by the HapMap Consortium.</p><p>Potential functional roles of associated non-coding variants were explored using the online UCSC Genome Browser<sup><xref ref-type="bibr" rid="bib54">54</xref></sup> with ENCODE tracks<sup><xref ref-type="bibr" rid="bib55">55</xref></sup> and the Broad Institute's Haploreg online resource.<sup><xref ref-type="bibr" rid="bib56">56</xref></sup></p></sec><sec><title>Data analysis</title><p>All subjects randomized to the double-blind crossover phase were included in the responder analyses. Descriptive statistics are reported as the mean&#x000b1;s.d. Before examining allelic effects on response, a general linear model was constructed using the ABC-hyperactivity for each gene variant examined to test for the presence of a positive dose effect (for example, if a treatment effect existed). Dose (low, medium, high or placebo), genotype and the interaction dose by genotype were then entered as predictor variables of parent-rated ABC-hyperactivity scores. The primary analyses were response by genotype compared using &#x003c7;<sup>2</sup> analyses or Fisher's exact tests. As the <italic>DRD3</italic> gly allele is the minor variant and some prior reports have shown biological differences between ser/ser and ser/gly versus gly/gly genotype groups, we restricted our comparison accordingly.<sup><xref ref-type="bibr" rid="bib57">57</xref></sup> As some investigators have noted significant moderation of stimulant effects of DRD4 variants in typically developing children specifying genotypes by the presence of 0, 1 or 2 copies of the &#x02018;7' allele,<sup><xref ref-type="bibr" rid="bib19">19</xref></sup> we also performed a similar three-way grouped analysis for this variant. Based on the fact that the previous literature on the <italic>SLC6A3</italic> VNTR has shown significant effects for 9/9 homozygotes, we analyzed our data according to this model.<sup><xref ref-type="bibr" rid="bib22">22</xref></sup> Statistical significance was set as <italic>P</italic>&#x0003c;0.05, and <italic>P</italic>&#x0003c;0.002 with correction for multiple testing.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Sixty-six children with autistic disorder (<italic>n</italic>=47), Asperger's disorder (<italic>n</italic>=5) or pervasive developmental disorder, not otherwise specified (<italic>n</italic>=14) completed the test dose phase and entered the double-blind crossover phase. Six subjects discontinued during the test dose phase. Of the 72 subjects who entered the trial, 7 subjects were unable or refused to provide samples for DNA and data were missing for one subject, leaving 64 subjects for genotyping. Sixteen subjects received an additional week of medium dose during the crossover phase because of moderate or greater side effects to the high dose in the test dose phase. Fifty-eight subjects were able to complete all 4 weeks of the crossover with the remainder leaving either because of adverse events (<italic>n</italic>=7) or for other reasons (<italic>n</italic>=1). The mean age of the subjects in this report was 6.90 years (&#x000b1;2.2, range 5.0&#x02013;13.0); 75.9&#x00025; were Caucasian, 87.9&#x00025; were male; the mean intelligence quotient was 65.0 (&#x000b1;33.3 range=16&#x02013;135). Neither age, ethnicity nor diagnosis was a significant covariate.</p><p><xref rid="tbl1" ref-type="table">Table 1</xref> shows parent and teacher rated SNAP-ADHD, SNAP-ODD and ABC-hyperactivity at baseline before entry into the double-blind phase. In general, subjects in the study had moderately severe symptoms of ADHD, and the optimal dose week demonstrated a moderate benefit associated with significantly reduced ABC-hyperactivity ratings and lower CGI-I scores. Analyses of ABC-hyperactivity scores across all four dose assessments showed a main effect for dose for all genotypes (all <italic>P</italic>&#x0003c;0.001). Variability in individual dose-response trajectories and optimal dose was substantial (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>After grouping subjects by <italic>a priori</italic> defined responder or non-responder categories, we analyzed the association of genotypes with responder status. <xref rid="tbl2" ref-type="table">Table 2</xref> reports the results of &#x003c7;<sup>2</sup> tests for genotype by response. Nominally significant responder by genotype effects (<xref ref-type="fig" rid="fig2">Figure 2</xref>) were noted for the dopamine receptors <italic>DRD1</italic> rs5326 (<italic>P</italic>=0.006, <xref ref-type="fig" rid="fig2">Figure 2a</xref>) and rs4867798 (<italic>P</italic>&#x0003c;0.05, <xref ref-type="fig" rid="fig2">Figure 2b</xref>), <italic>DRD3</italic> ser9gly rs6280 (<italic>P</italic>&#x0003c;0.05, <xref ref-type="fig" rid="fig2">Figure 2c</xref>) and <italic>DRD4</italic> rs11246226 (<italic>P</italic>&#x0003c;0.04, <xref ref-type="fig" rid="fig2">Figure 2d</xref>); the adrenergic receptor <italic>ADRA2A</italic> rs1800544 (<italic>P</italic>&#x0003c;0.02, <xref ref-type="fig" rid="fig2">Figure 2e</xref>); the dopamine and serotonin transporters <italic>SLC6A3</italic> VNTR (<italic>P</italic>&#x0003c;0.05, <xref ref-type="fig" rid="fig2">Figure 2f</xref>) and <italic>SLC6A4</italic> STin2 VNTR (<italic>P</italic>&#x0003c;0.05, <xref ref-type="fig" rid="fig2">Figure 2g</xref>), respectively; and the catabolic enzyme <italic>COMT val/met</italic> rs4680 (<italic>P</italic>&#x0003c;0.05, <xref ref-type="fig" rid="fig2">Figure 2h</xref>). No significant effects on response were evident for the <italic>DRD2</italic>, <italic>DRD5</italic> or <italic>MAOA/B</italic> variants tested.</p><p>In an effort to further reveal possible interactions between dose condition and genotype, in secondary analyses we tested the relationship between ABC-hyperactivity scores across the four treatment conditions for main effects of dose, genotype and dose by genotype interaction using analysis of covariance with baseline ABC-hyperactivity scores as the covariate. Results (<xref rid="tbl2" ref-type="table">Table 2</xref>) showed significant dose by genotype interactions for promoter SNPs in <italic>DRD4</italic> rs11246226 (<italic>P</italic>&#x0003c;0.02) and <italic>SLC6A4</italic> rs12150214 (<italic>P</italic>&#x0003c;0.03). In contrast to previous findings, <italic>SLC6A3</italic> VNTR analysis did not yield dose by genotype effects;<sup><xref ref-type="bibr" rid="bib22">22</xref></sup> however, our power to detect these effects was very low given the small number of subjects with the 9/9 genotype (<italic>n</italic>=3), all of whom were responders.</p><p>The 14 subjects who dropped because of intolerability were similar to those completing the study (83&#x00025; male, 83&#x00025; Caucasian, mean age 8.6 years). Genetic comparison of those 14 subjects to trial completers revealed a protective effect for carriers of the minor allele at <italic>DRD2</italic> synonymous variant rs6275. Intolerability increased from 4&#x00025; in minor allele carriers to 23&#x00025; in those homozygous for the common allele (<italic>P</italic>&#x0003c;0.001), a result surviving correction for multiple testing. The DRD3 variant rs6280 (Ser9Gly) was nominally associated with tolerability, as intolerability increased from 3&#x00025; in common allele homozygotes to 18&#x00025; in carriers of the minor allele (<italic>P</italic>=0.031), suggesting that the minor allele is a risk factor for stimulant intolerance.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>In this first pharmacogenetic study of MPH in a modest but homogeneous (90&#x00025; male, 90&#x00025; stimulant naive) sample of children with ASD, improvement in hyperactive-impulsive symptoms associated with MPH administration was moderated significantly by several gene variants comprising elements of monoaminergic systems for dopamine, norepinephrine and serotonin, all of which have known regulatory effects on motor activity, and higher order cognitive functions.<sup><xref ref-type="bibr" rid="bib58">58</xref>, <xref ref-type="bibr" rid="bib59">59</xref>, <xref ref-type="bibr" rid="bib60">60</xref></sup> Of the 10 candidate genes queried based on prior research, our data supported a contribution of genetic variation in 7 genes (<italic>SLC6A4</italic>, <italic>SLC6A3</italic>, <italic>DRD1</italic>, <italic>DRD3</italic>, <italic>DRD4</italic>, <italic>COMT</italic> and <italic>ADRA2A</italic>) to clinical MPH response. Although our sample size did not provide adequate power for multiple comparison correction, the number of positive associations observed is unlikely to occur by chance. An exact binomial calculation for the probability of 7 or more significant hits out of 36 variants, whereas not an exact <italic>P</italic>-value, suggests that many of these associations are in fact true positives (<italic>P</italic>&#x0003c;0.002). These genetic effects may reveal some of the sources of marked variability in clinical outcomes observed in this trial and in clinical experience for this common treatment in ASD; in this trial only half of all subjects responded to moderate-dose MPH.</p><p>Our results add support to the previous suggestions of contributions of variants in several genes influencing MPH response in ADHD (<italic>SLC6A4</italic>, <italic>SLC6A3</italic>, <italic>DRD4</italic>, <italic>COMT</italic> and <italic>ADRA2A</italic>) but in some cases suggest new loci not previously implicated as MPH-response modifiers (<italic>SLC6A4</italic> STin2 VNTR and <italic>DRD4</italic> rs11246226). In addition, we also identified new associations with other genes not extensively examined thus far in the ADHD literature (<italic>DRD1</italic> rs5326 and rs4867798<italic>, DRD3</italic> ser9gly rs6280), but rational candidates given their distribution and known cognitive and behavioral pharmacologic effects of agonists and antagonists at these targets. Our findings should encourage other investigations of these variants in larger samples.</p><p>Not surprisingly, DA transporter and DA receptor variants showed the strongest associations with treatment response. In contrast to earlier studies,<sup><xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib20">20</xref>, <xref ref-type="bibr" rid="bib61">61</xref></sup> our data agree with the recent report by Froehlich <italic>et al.</italic>,<sup><xref ref-type="bibr" rid="bib22">22</xref></sup> showing an enhanced MPH response in <italic>SLC6A3</italic> 9/9 homozygotes. DRD1, highly expressed in cortex and striatum, is important in cognitive and motor control,<sup><xref ref-type="bibr" rid="bib62">62</xref></sup> and may be a minor ADHD risk gene.<sup><xref ref-type="bibr" rid="bib63">63</xref>, <xref ref-type="bibr" rid="bib64">64</xref></sup>
<italic>DRD1</italic> was most strongly associated with clinical response with two SNPs (rs5326 and rs4867798; <italic>P</italic>=0.006 and <italic>P</italic>=0.043, respectively) in our sample. <italic>In silico</italic> exploration suggests that both <italic>DRD1</italic> SNPs (rs5326 and rs4867798) may be functional, as they map to areas of open chromatin in the 5&#x02032; and 3&#x02032; untranslated regions and appear to alter binding sites for the transcriptional repressor ZNF263 and the transcriptional activator POU2F1 respectively. The non-synonymous Ser9Gly variant in <italic>DRD3</italic> was also associated with MPH response. Ser/ser homozygotes demonstrated greater response than glycine allele carriers. Finally, we observed an association of a promoter SNP (rs11246226) in <italic>DRD4</italic> with both clinical response as well as a genotype by dose interaction. <italic>DRD4</italic> is well known as a minor risk gene for ADHD<sup><xref ref-type="bibr" rid="bib65">65</xref></sup> and the exon 3 VNTR has been extensively studied for associations with cognitive phenotypes and drug response, but studies have not tested effects of other variants at this locus. It is difficult to ascertain the likely sources of differences between our data and some previous studies for effects of the <italic>DRD4</italic> exon 3 VNTR variant in particular, however, we note the literature is quite inconsistent with respect to its associations with response, even in reports from the same group.<sup><xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib25">25</xref></sup> Consistent with other reports, <italic>DRD2</italic> was not found to associate with clinical response to MPH, surprising given the multiple functional variants and stimulant-induced displacement of DRD2 binding following acute MPH.<sup><xref ref-type="bibr" rid="bib40">40</xref></sup> Taken together, our findings of associations between <italic>DRD1</italic>, <italic>DRD3</italic> and <italic>DRD4</italic> and response measures suggest that common variants in the DA pathway do exert influences on the effects of MPH and moderate its DA-mediated impact on behavior.</p><p>Despite our modest sample size, the multiple (admittedly nominal) associations with several dopamine receptor subtypes (<italic>DRD1</italic>, <italic>DRD3</italic> and <italic>DRD4</italic>) lead us to speculate that the effects of gene variants in these targets may be amplified by ASD-related dopamine dysregulation. We posit that ASD-related differences in DA function may influence the interaction between gene variants and MPH, as evidence supports increased DA turnover (increased frontal uptake of<sup><xref ref-type="bibr" rid="bib18">18</xref></sup> fluoro-3,4-dihydroxy-5-fluorophenylalanine and increased cerebrospinal fluid homovanillic acid) in ASD as well as increased dopamine transporter binding.<sup><xref ref-type="bibr" rid="bib44">44</xref>, <xref ref-type="bibr" rid="bib45">45</xref>, <xref ref-type="bibr" rid="bib66">66</xref></sup> Such ASD-related differences may shift dose-response, enhancing or distorting pharmacogenetic relationships seen in typically developing children. Indeed, the high rate of MPH intolerance, several-fold greater than reports from typically developing children, suggests greater sensitivity to MPH pro-dopaminergic effects in ASD. These data add modest support to the notion that although common gene variants influence psychostimulant response in both typically and atypically developing subjects with hyperactivity, there are some possible differences because of underlying disorder neurobiology.</p><p>Our findings also reinforce the emerging view that beneficial effects of stimulants are multifactorial in their mechanism, reflecting drug effects on serotonergic and noradrenergic functions in addition to dopaminergic actions.<sup><xref ref-type="bibr" rid="bib59">59</xref></sup> However, it is possible that identified non-DA gene effects may be also mediated via downstream effects on dopaminergic neurotransmission. For example, <italic>SLC6A4</italic> alleles associated with high expression (LPR <italic>l</italic> and particularly STin2 12 alleles), have been suggested to moderate mood effects of amphetamine in healthy subjects<sup><xref ref-type="bibr" rid="bib52">52</xref></sup> and in typically developing children with ADHD, and LPR <italic>/</italic>/<italic>l</italic> homozygous subjects showed less improvement in global functioning with MPH.<sup><xref ref-type="bibr" rid="bib34">34</xref></sup> However, opposing effects of the two variants were seen on different outcome variables.<sup><xref ref-type="bibr" rid="bib19">19</xref></sup> Mice lacking <italic>SLC6A3</italic> still demonstrate reductions in activity from MPH, apparently mediated via 5HT.<sup><xref ref-type="bibr" rid="bib33">33</xref></sup> The lower response rates in our 10/12 and 12/12 genotype subjects is in line with the known effects of the 12 allele on higher transporter expression. We also noted a tagging SNP in the first intron of <italic>SLA6A4,</italic> just upstream of the translational start, was associated with differential response at high dose MPH. This SNP, while intronic, is in a linkage disequilibrium block showing multiple enhancer histone marks suggesting an area of active transcriptional regulation.</p><p>Similarly, these data also contribute to the growing support for the involvement of the noradrenergic system in stimulant response in ADHD, consistent with direct effects of stimulant-induced NE release<sup><xref ref-type="bibr" rid="bib58">58</xref></sup> and the reciprocal relationship of noradrenergic&#x02013;dopaminergic pathways.<sup><xref ref-type="bibr" rid="bib67">67</xref></sup> Our data did identify a moderating effect of the <italic>ADRA2A</italic> promoter SNP rs1800544 and clinical response, extending prior observations.<sup><xref ref-type="bibr" rid="bib31">31</xref>, <xref ref-type="bibr" rid="bib32">32</xref></sup> Online database mining supports a functional effect of the associated variant, as this SNP maps to a site of open chromatin in the <italic>ADRA2A</italic> promoter with histone marks and binding sites for the transcription factors RAD21 and CTCF, which have a role in promoter methylation, and ultimately expression.</p><p>Relevant to dopaminergic and noradrenergic transmission, we found support for earlier observations<sup><xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib38">38</xref>, <xref ref-type="bibr" rid="bib39">39</xref></sup> that variants in <italic>COMT</italic> moderated clinical benefit from MPH. However, contrary to studies in healthy subjects<sup><xref ref-type="bibr" rid="bib37">37</xref></sup> and typical ADHD, in our data set <italic>met</italic>-carriers showed a greater reduction in hyperactivity with MPH treatment than <italic>val/val</italic> homozygotes. Indeed, <italic>met/met</italic> subjects had a 75&#x00025; (9/12) response rate versus 37&#x00025; (7/19) for <italic>val/val</italic> homozygotes, a twofold differential. If ASD is associated with reduced tonic dopamine (consequences of increased DAT and increased presynaptic uptake), the resulting hypothesized shift in dose-response could favor <italic>met/met</italic> individuals, as <italic>val/val</italic> subjects may lack sufficient dopamine availability to overcome reduced DA tone despite MPH releasing effects.</p><p>Our report is novel in our analyses of possible genetic underpinnings of stimulant intolerance, not heretofore researched in the ADHD pharmacogenetic literature. A <italic>DRD2</italic> variant, rs6275, not associated with response, was significantly associated with MPH intolerability and remained significant after correction. Homozygotes for the common allele at rs6275 showed a sixfold greater rate of intolerance. The non-synonymous Ser9Gly (rs6280) variant in <italic>DRD3</italic> was associated with MPH response and tolerability, as gly allele carriers were highly likely to either be intolerant of MPH and/or be less responsive than ser/ser homozygotes. These variants merit additional investigation in relationship to a range of stimulant-induced adverse effects in much larger samples.</p><p>Strengths of our findings include the thorough genetic analyses, use of a rigorous study design including comparisons of placebo versus multiple fixed-dose treatment conditions, blinded evaluations by multiple informants (parents, teachers and study clinicians), application of a careful, multi-informant based and clinically relevant definition of responder status, and recruitment of a largely male, stimulant-naive, homogenous sample. Relative to the only other small (<italic>n</italic>&#x02a7d;13), controlled studies of stimulants in ASD, our sample is more homogenous with respect to sex, ethnicity, treatment history and diagnosis.<sup><xref ref-type="bibr" rid="bib11">11</xref>, <xref ref-type="bibr" rid="bib12">12</xref></sup> Capitalizing on the strengths of our design, we were able to examine genetic effects observed under optimal treatment conditions, as determined by blinded assessments and multiple raters.</p><p>Limitations of this work include the short duration of MPH treatment observation periods, the modest sample size and the restrictions of genotyping to selected candidate genes. Our observations could be associated with an increased risk of type I statistical error.</p><p>In summary, the reduction of hyperactivity by MPH in individuals with ASD may be moderated at the level of individual genetic variability, particularly at loci that influence monoaminergic signaling. ADHD symptoms are common in ASD, and MPH remains the best empirically validated treatment for this target, although variation in response and tolerability is large. Additional studies replicating our observations and identifying other potential individual predictors of response to MPH in individuals with ASD are strongly needed. Improving overall outcomes from long-term intervention efforts for ASD remains a major clinical and public health challenge.</p></sec></body><back><ack><p>The RUPP Autism Network comprises the following investigators listed by role and study site: Ohio State University: principal investigator Michael G Aman, PhD, co-investigators L Eugene Arnold, MEd, MD, Yaser Ramadan, MD, Andrea Witwer, MA, Ronald Lindsay, MD and Patricia Nash, MD; University of California at Los Angeles: principal investigator James T McCracken, MD, co-investigators Bhavik Shah, MD, James McGough, MD, Pegeen Cronin, PhD, Lisa Lee, BA; Indiana University: principal investigator Christopher J McDougle, MD, co-investigators David Posey, MD, Naomi Swiezy, PhD, Arlene Kohn, BA; Yale University: principal investigator Lawrence Scahill, MSN, PhD, co-investigators Andres Martin, MD, Kathleen Koenig, MSN, Fred Volkmar, MD, Deirdre Carroll, MSN, Allison Lancor, BS; Kennedy Krieger Institute: principal investigator Elaine Tierney, MD, co-investigators Jaswinder Ghuman, MD, Nilda Gonzalez, MD, Marco Grados, MD; National Institute of Mental Health: principal investigator Benedetto Vitiello, MD, co-investigator Louise Ritz, MBA; statisticians: Shirley Z Chuang, MS, Mark Davies, MPH, of Columbia University; data management: James Robinson, MEd, Don McMahon, MS, Nathan Kline Institute. Research supported by NIMH contracts N01 MH-70070 (principal investigator: Dr McCracken), N01 MH-70009 (principal investigator: Dr Scahill), N01 MH-70001 (principal investigator: Dr McDougle), and N01 MH 80011 (principal investigator: Dr Aman); by NIH Division of Research Resources General Clinical Research Center grants M01 RR-00750 (to Indiana University), M01 RR-00052 (to John Hopkins University), M01 RR-00034 (to Ohio University) and M01 RR-06022 (to Yale University); by NIMH grants MH-01805 (to Dr McCracken) NIMH grants MH094613 and T32MH073517 (Dr Nurmi) and MH-68627 (to Dr Posey); and by funding from the Korczak Foundation (to Dr Scahill). The opinions and assertions contained in this report are the private views of the authors and are not to be construed as official or as reflecting the views of the National Institute of Mental Health, the National Institutes of Health, or the Department of Health and Human Services.</p></ack><notes><p>Dr Aman has received consulting fees from Bristol-Myers Squibb, BioMarin, Roche and Supernus. Dr Aman also reports research support from Bristol-Myers Squibb and Johnson and Johnson. Dr Arnold has received research funding from Curemark, Shire and Lilly, and has consulted on advisory boards for AstraZeneca, Biomarin, Novartis, Noven, Seaside Therapeutics and Shire. Dr McCracken reports receiving consulting fees from BioMarin, Novartis and PharmaNet; he also reports research support from Bristol-Myers Squibb, Roche and Seaside Therapeutics. Dr McDougle reports having received consultant fees from Bristol-Myers Squibb, Hoffman-LaRoche and Forest Research Institute; he has also received research support and is on the speakers' bureau of Bristol-Myers Squibb. Dr Scahill reports receiving consultant fees from Brackett, Pfizer, Hoffman, BioMarin; he has also received research support from Pfizer, Shire and Hoffman. The remaining authors declare no conflict of interest.</p></notes><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Centers for Disease Control (2007)</collab></person-group><article-title>Prevalence of autism spectrum disorders, 14 Sites, United States, 2002</article-title><source>Morbidity Mortality Weekly Rep</source><year>2007</year><volume>56</volume><fpage>12</fpage><lpage>28</lpage></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecavalier</surname><given-names>L</given-names></name></person-group><article-title>Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification</article-title><source>J Autism Dev Disord</source><year>2006</year><volume>36</volume><fpage>1101</fpage><lpage>1114</lpage><pub-id pub-id-type="pmid">16897387</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>McCracken</surname><given-names>JT</given-names></name></person-group><article-title>Disruptive behaviors in children with autism spectrum disorders</article-title>In: Coyle JHE, Kolevzon A (eds)<source>Textbook of Autism Spectrum Disorders</source><publisher-name>American Psychiatric Publishing: New York, NY, USA</publisher-name><year>2011</year><fpage>159</fpage><lpage>167</lpage></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simonoff</surname><given-names>E</given-names></name><name><surname>Pickles</surname><given-names>A</given-names></name><name><surname>Charman</surname><given-names>T</given-names></name><name><surname>Chandler</surname><given-names>S</given-names></name><name><surname>Loucas</surname><given-names>T</given-names></name><name><surname>Baird</surname><given-names>G</given-names></name></person-group><article-title>Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2008</year><volume>47</volume><fpage>921</fpage><lpage>929</lpage><pub-id pub-id-type="pmid">18645422</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frazier</surname><given-names>JA</given-names></name><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Bellordre</surname><given-names>CA</given-names></name><name><surname>Garfield</surname><given-names>SB</given-names></name><name><surname>Geller</surname><given-names>DA</given-names></name><name><surname>Coffey</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Should the diagnosis of attention-deficit/hyperactivity disorder be considered in children with pervasive developmental disorder</article-title><source>J Attention Disord</source><year>2001</year><volume>4</volume><fpage>203</fpage><lpage>211</lpage></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>S</given-names></name><name><surname>Schwebach</surname><given-names>AJ</given-names></name></person-group><article-title>The comorbidity of pervasive developmental disorder and attention deficit hyperactivity disorder: results of a retrospective chart review</article-title><source>J Autism Dev Disord</source><year>2004</year><volume>34</volume><fpage>329</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">15264500</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aman</surname><given-names>MG</given-names></name><name><surname>Lam</surname><given-names>KS</given-names></name><name><surname>Van Bourgondien</surname><given-names>ME</given-names></name></person-group><article-title>Medication patterns in patients with autism: temporal, regional, and demographic influences</article-title><source>J Child Adolesc Psychopharmacol</source><year>2005</year><volume>15</volume><fpage>116</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">15741793</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esbensen</surname><given-names>AJ</given-names></name><name><surname>Greenberg</surname><given-names>JS</given-names></name><name><surname>Seltzer</surname><given-names>MM</given-names></name><name><surname>Aman</surname><given-names>MG</given-names></name></person-group><article-title>A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders</article-title><source>J Autism Dev Disord</source><year>2009</year><volume>39</volume><fpage>1339</fpage><lpage>1349</lpage><pub-id pub-id-type="pmid">19434487</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>M</given-names></name><name><surname>Fish</surname><given-names>B</given-names></name><name><surname>David</surname><given-names>R</given-names></name><name><surname>Shapiro</surname><given-names>T</given-names></name><name><surname>Collins</surname><given-names>P</given-names></name><name><surname>Koh</surname><given-names>C</given-names></name></person-group><article-title>Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children</article-title><source>J Autism Child Schizophr</source><year>1972</year><volume>2</volume><fpage>343</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">4581614</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>M</given-names></name><name><surname>Small</surname><given-names>AM</given-names></name><name><surname>Collins</surname><given-names>PJ</given-names></name><name><surname>Friedman</surname><given-names>E</given-names></name><name><surname>David</surname><given-names>R</given-names></name><name><surname>Genieser</surname><given-names>N</given-names></name></person-group><article-title>Levodopa and levoamphetamine: a crossover study in young schizophrenic children</article-title><source>Curr Ther Res Clin Exp</source><year>1976</year><volume>19</volume><fpage>70</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">812668</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintana</surname><given-names>H</given-names></name><name><surname>Birmaher</surname><given-names>B</given-names></name><name><surname>Stedge</surname><given-names>D</given-names></name><name><surname>Lennon</surname><given-names>S</given-names></name><name><surname>Freed</surname><given-names>J</given-names></name><name><surname>Bridge</surname><given-names>J</given-names></name><etal/></person-group><article-title>Use of methylphenidate in the treatment of children with autistic disorder</article-title><source>J Autism Dev Disord</source><year>1995</year><volume>25</volume><fpage>283</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">7559293</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Handen</surname><given-names>BL</given-names></name><name><surname>Johnson</surname><given-names>CR</given-names></name><name><surname>Lubetsky</surname><given-names>M</given-names></name></person-group><article-title>Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder</article-title><source>J Autism Dev Disord</source><year>2000</year><volume>30</volume><fpage>245</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">11055460</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aman</surname><given-names>MG</given-names></name><name><surname>Singh</surname><given-names>NN</given-names></name><name><surname>Stewart</surname><given-names>AW</given-names></name><name><surname>Field</surname><given-names>CJ</given-names></name></person-group><article-title>The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects</article-title><source>Am J Ment Defic</source><year>1985</year><volume>89</volume><fpage>485</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">3993694</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aman</surname><given-names>MG</given-names></name><name><surname>Singh</surname><given-names>NN</given-names></name><name><surname>Stewart</surname><given-names>AW</given-names></name><name><surname>Field</surname><given-names>CJ</given-names></name></person-group><article-title>Psychometric characteristics of the aberrant behavior checklist</article-title><source>Am J Ment Defic</source><year>1985</year><volume>89</volume><fpage>492</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">3158201</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posey</surname><given-names>DJ</given-names></name><name><surname>Aman</surname><given-names>MG</given-names></name><name><surname>McCracken</surname><given-names>JT</given-names></name><name><surname>Scahill</surname><given-names>L</given-names></name><name><surname>Tierney</surname><given-names>E</given-names></name><name><surname>Arnold</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures</article-title><source>Biol Psychiatry</source><year>2007</year><volume>61</volume><fpage>538</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">17276750</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenhill</surname><given-names>LL</given-names></name><name><surname>Abikoff</surname><given-names>HB</given-names></name><name><surname>Arnold</surname><given-names>LE</given-names></name><name><surname>Cantwell</surname><given-names>DP</given-names></name><name><surname>Conners</surname><given-names>CK</given-names></name><name><surname>Elliott</surname><given-names>G</given-names></name><etal/></person-group><article-title>Medication treatment strategies in the MTA Study: relevance to clinicians and researchers</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>1996</year><volume>35</volume><fpage>1304</fpage><lpage>1313</lpage><pub-id pub-id-type="pmid">8885584</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>MA</given-names></name><name><surname>McGough</surname><given-names>JJ</given-names></name></person-group><article-title>The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy</article-title><source>Child Adolesc Psychiatr Clin N Am</source><year>2008</year><volume>17</volume><fpage>475</fpage><lpage>490</lpage>xi-xii.<pub-id pub-id-type="pmid">18295157</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Nurmi</surname><given-names>EL</given-names></name><name><surname>McCracken</surname><given-names>JT</given-names></name></person-group><article-title>Genetics in child psychiatry</article-title>In Sadock BJ, Sadock VA, Ruiz P, Kaplan HI, Ovid Technologies I (eds)<source>Kaplan &#x00026; Sadock's Comprehensive Textbook of Psychiatry, IXth edn</source><publisher-name>Wolters Kluwer Health/Lippincott Williams &#x00026; Wilkins: Philadelphia, PA, USA</publisher-name><year>2009</year></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGough</surname><given-names>JJ</given-names></name><name><surname>McCracken</surname><given-names>JT</given-names></name><name><surname>Loo</surname><given-names>SK</given-names></name><name><surname>Manganiello</surname><given-names>M</given-names></name><name><surname>Leung</surname><given-names>MC</given-names></name><name><surname>Tietjens</surname><given-names>JR</given-names></name><etal/></person-group><article-title>A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2009</year><volume>48</volume><fpage>1155</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">19858760</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>MA</given-names></name><name><surname>Waldman</surname><given-names>ID</given-names></name><name><surname>Sarampote</surname><given-names>CS</given-names></name><name><surname>Seymour</surname><given-names>KE</given-names></name><name><surname>Robb</surname><given-names>AS</given-names></name><name><surname>Conlon</surname><given-names>C</given-names></name><etal/></person-group><article-title>Dopamine transporter genotype and methylphenidate dose response in children with ADHD</article-title><source>Neuropsychopharmacology</source><year>2005</year><volume>30</volume><fpage>1374</fpage><lpage>1382</lpage><pub-id pub-id-type="pmid">15827573</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purper-Ouakil</surname><given-names>D</given-names></name><name><surname>Wohl</surname><given-names>M</given-names></name><name><surname>Orejarena</surname><given-names>S</given-names></name><name><surname>Cortese</surname><given-names>S</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Asch</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pharmacogenetics of methylphenidate response in attention deficit/hyperactivity disorder: association with the dopamine transporter gene (SLC6A3)</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2008</year><volume>147B</volume><fpage>1425</fpage><lpage>1430</lpage><pub-id pub-id-type="pmid">18563707</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Froehlich</surname><given-names>TE</given-names></name><name><surname>Epstein</surname><given-names>JN</given-names></name><name><surname>Nick</surname><given-names>TG</given-names></name><name><surname>Melguizo Castro</surname><given-names>MS</given-names></name><name><surname>Stein</surname><given-names>MA</given-names></name><name><surname>Brinkman</surname><given-names>WB</given-names></name><etal/></person-group><article-title>Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2011</year><volume>50</volume><fpage>1129</fpage><lpage>1139 e1122</lpage><pub-id pub-id-type="pmid">22024001</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheon</surname><given-names>KA</given-names></name><name><surname>Kim</surname><given-names>BN</given-names></name><name><surname>Cho</surname><given-names>SC</given-names></name></person-group><article-title>Association of 4-repeat allele of the dopamine D4 receptor gene exon III polymorphism and response to methylphenidate treatment in Korean ADHD children</article-title><source>Neuropsychopharmacology</source><year>2007</year><volume>32</volume><fpage>1377</fpage><lpage>1383</lpage><pub-id pub-id-type="pmid">17077808</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamarman</surname><given-names>S</given-names></name><name><surname>Fossella</surname><given-names>J</given-names></name><name><surname>Ulger</surname><given-names>C</given-names></name><name><surname>Brimacombe</surname><given-names>M</given-names></name><name><surname>Dermody</surname><given-names>J</given-names></name></person-group><article-title>Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetic study</article-title><source>J Child Adolesc Psychopharmacol</source><year>2004</year><volume>14</volume><fpage>564</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">15662148</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGough</surname><given-names>J</given-names></name><name><surname>McCracken</surname><given-names>J</given-names></name><name><surname>Swanson</surname><given-names>J</given-names></name><name><surname>Riddle</surname><given-names>M</given-names></name><name><surname>Kollins</surname><given-names>S</given-names></name><name><surname>Greenhill</surname><given-names>L</given-names></name><etal/></person-group><article-title>Pharmacogenetics of methylphenidate response in preschoolers with ADHD</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2006</year><volume>45</volume><fpage>1314</fpage><lpage>1322</lpage><pub-id pub-id-type="pmid">17023870</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahir</surname><given-names>E</given-names></name><name><surname>Yazgan</surname><given-names>Y</given-names></name><name><surname>Cirakoglu</surname><given-names>B</given-names></name><name><surname>Ozbay</surname><given-names>F</given-names></name><name><surname>Waldman</surname><given-names>I</given-names></name><name><surname>Asherson</surname><given-names>PJ</given-names></name></person-group><article-title>Association and linkage of DRD4 and DRD5 with attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children</article-title><source>Mol Psychiatry</source><year>2000</year><volume>5</volume><fpage>396</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">10889550</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kooij</surname><given-names>JS</given-names></name><name><surname>Boonstra</surname><given-names>AM</given-names></name><name><surname>Vermeulen</surname><given-names>SH</given-names></name><name><surname>Heister</surname><given-names>AG</given-names></name><name><surname>Burger</surname><given-names>H</given-names></name><name><surname>Buitelaar</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1)</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2008</year><volume>147B</volume><fpage>201</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">17955457</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Meulen</surname><given-names>EM</given-names></name><name><surname>Bakker</surname><given-names>SC</given-names></name><name><surname>Pauls</surname><given-names>DL</given-names></name><name><surname>Oteman</surname><given-names>N</given-names></name><name><surname>Kruitwagen</surname><given-names>CL</given-names></name><name><surname>Pearson</surname><given-names>PL</given-names></name><etal/></person-group><article-title>High sibling correlation on methylphenidate response but no association with DAT1-10R homozygosity in Dutch sibpairs with ADHD</article-title><source>J Child Psychol Psychiatry</source><year>2005</year><volume>46</volume><fpage>1074</fpage><lpage>1080</lpage><pub-id pub-id-type="pmid">16178931</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeni</surname><given-names>CP</given-names></name><name><surname>Guimaraes</surname><given-names>AP</given-names></name><name><surname>Polanczyk</surname><given-names>GV</given-names></name><name><surname>Genro</surname><given-names>JP</given-names></name><name><surname>Roman</surname><given-names>T</given-names></name><name><surname>Hutz</surname><given-names>MH</given-names></name><etal/></person-group><article-title>No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2007</year><volume>144B</volume><fpage>391</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">17171656</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruber</surname><given-names>R</given-names></name><name><surname>Joober</surname><given-names>R</given-names></name><name><surname>Grizenko</surname><given-names>N</given-names></name><name><surname>Leventhal</surname><given-names>BL</given-names></name><name><surname>Cook</surname><given-names>EH</given-names><suffix>Jr</suffix></name><name><surname>Stein</surname><given-names>MA</given-names></name></person-group><article-title>Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder</article-title><source>J Child Adolesc Psychopharmacol</source><year>2009</year><volume>19</volume><fpage>233</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">19519258</pub-id></mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polanczyk</surname><given-names>G</given-names></name><name><surname>Zeni</surname><given-names>C</given-names></name><name><surname>Genro</surname><given-names>JP</given-names></name><name><surname>Guimaraes</surname><given-names>AP</given-names></name><name><surname>Roman</surname><given-names>T</given-names></name><name><surname>Hutz</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder</article-title><source>Arch Gen Psychiatry</source><year>2007</year><volume>64</volume><fpage>218</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">17283289</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname><given-names>TL</given-names></name><name><surname>Pianca</surname><given-names>TG</given-names></name><name><surname>Roman</surname><given-names>T</given-names></name><name><surname>Hutz</surname><given-names>MH</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name><name><surname>Schmitz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Adrenergic alpha2A receptor gene and response to methylphenidate in attention-deficit/hyperactivity disorder-predominantly inattentive type</article-title><source>J Neural Transm</source><year>2008</year><volume>115</volume><fpage>341</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">18200436</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gainetdinov</surname><given-names>RR</given-names></name><name><surname>Wetsel</surname><given-names>WC</given-names></name><name><surname>Jones</surname><given-names>SR</given-names></name><name><surname>Levin</surname><given-names>ED</given-names></name><name><surname>Jaber</surname><given-names>M</given-names></name><name><surname>Caron</surname><given-names>MG</given-names></name></person-group><article-title>Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity</article-title><source>Science</source><year>1999</year><volume>283</volume><fpage>397</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">9888856</pub-id></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seeger</surname><given-names>G</given-names></name><name><surname>Schloss</surname><given-names>P</given-names></name><name><surname>Schmidt</surname><given-names>MH</given-names></name></person-group><article-title>Marker gene polymorphisms in hyperkinetic disorder&#x02014;predictors of clinical response to treatment with methylphenidate</article-title><source>Neurosci Lett</source><year>2001</year><volume>313</volume><fpage>45</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">11684336</pub-id></mixed-citation></ref><ref id="bib35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alfimova</surname><given-names>MV</given-names></name><name><surname>Golimbet</surname><given-names>VE</given-names></name><name><surname>Gritsenko</surname><given-names>IK</given-names></name><name><surname>Lezheiko</surname><given-names>TV</given-names></name><name><surname>Abramova</surname><given-names>LI</given-names></name><name><surname>Strel'tsova</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Interaction of dopamine system genes and cognitive functions in patients with schizophrenia and their relatives and in healthy subjects from the general population</article-title><source>Neurosci Behav Physiol</source><year>2007</year><volume>37</volume><fpage>643</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">17763983</pub-id></mixed-citation></ref><ref id="bib36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Frias</surname><given-names>CM</given-names></name><name><surname>Annerbrink</surname><given-names>K</given-names></name><name><surname>Westberg</surname><given-names>L</given-names></name><name><surname>Eriksson</surname><given-names>E</given-names></name><name><surname>Adolfsson</surname><given-names>R</given-names></name><name><surname>Nilsson</surname><given-names>LG</given-names></name></person-group><article-title>Catechol O-methyltransferase Val158Met polymorphism is associated with cognitive performance in nondemented adults</article-title><source>J Cogn Neurosci</source><year>2005</year><volume>17</volume><fpage>1018</fpage><lpage>1025</lpage><pub-id pub-id-type="pmid">16102234</pub-id></mixed-citation></ref><ref id="bib37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattay</surname><given-names>VS</given-names></name><name><surname>Goldberg</surname><given-names>TE</given-names></name><name><surname>Fera</surname><given-names>F</given-names></name><name><surname>Hariri</surname><given-names>AR</given-names></name><name><surname>Tessitore</surname><given-names>A</given-names></name><name><surname>Egan</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>6186</fpage><lpage>6191</lpage><pub-id pub-id-type="pmid">12716966</pub-id></mixed-citation></ref><ref id="bib38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheon</surname><given-names>KA</given-names></name><name><surname>Jun</surname><given-names>JY</given-names></name><name><surname>Cho</surname><given-names>DY</given-names></name></person-group><article-title>Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder</article-title><source>Int Clin Psychopharmacol</source><year>2008</year><volume>23</volume><fpage>291</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">18703939</pub-id></mixed-citation></ref><ref id="bib39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kereszturi</surname><given-names>E</given-names></name><name><surname>Tarnok</surname><given-names>Z</given-names></name><name><surname>Bognar</surname><given-names>E</given-names></name><name><surname>Lakatos</surname><given-names>K</given-names></name><name><surname>Farkas</surname><given-names>L</given-names></name><name><surname>Gadoros</surname><given-names>J</given-names></name><etal/></person-group><article-title>Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2008</year><volume>147B</volume><fpage>1431</fpage><lpage>1435</lpage><pub-id pub-id-type="pmid">18214865</pub-id></mixed-citation></ref><ref id="bib40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Wang</surname><given-names>GJ</given-names></name><name><surname>Fowler</surname><given-names>JS</given-names></name><name><surname>Ding</surname><given-names>YS</given-names></name></person-group><article-title>Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder</article-title><source>Biol Psychiatry</source><year>2005</year><volume>57</volume><fpage>1410</fpage><lpage>1415</lpage><pub-id pub-id-type="pmid">15950015</pub-id></mixed-citation></ref><ref id="bib41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kollins</surname><given-names>SH</given-names></name><name><surname>Anastopoulos</surname><given-names>AD</given-names></name><name><surname>Lachiewicz</surname><given-names>AM</given-names></name><name><surname>FitzGerald</surname><given-names>D</given-names></name><name><surname>Morrissey-Kane</surname><given-names>E</given-names></name><name><surname>Garrett</surname><given-names>ME</given-names></name><etal/></person-group><article-title>SNPs in dopamine D2 receptor gene (DRD2) and norepinephrine transporter gene (NET) are associated with continuous performance task (CPT) phenotypes in ADHD children and their families</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2008</year><volume>147B</volume><fpage>1580</fpage><lpage>1588</lpage><pub-id pub-id-type="pmid">18821566</pub-id></mixed-citation></ref><ref id="bib42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>London</surname><given-names>ED</given-names></name><name><surname>Poldrack</surname><given-names>RA</given-names></name><name><surname>Farahi</surname><given-names>J</given-names></name><name><surname>Nacca</surname><given-names>A</given-names></name><name><surname>Monterosso</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity</article-title><source>J Neurosci</source><year>2009</year><volume>29</volume><fpage>14734</fpage><lpage>14740</lpage><pub-id pub-id-type="pmid">19940168</pub-id></mixed-citation></ref><ref id="bib43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieminen-von Wendt</surname><given-names>TS</given-names></name><name><surname>Metsahonkala</surname><given-names>L</given-names></name><name><surname>Kulomaki</surname><given-names>TA</given-names></name><name><surname>Aalto</surname><given-names>S</given-names></name><name><surname>Autti</surname><given-names>TH</given-names></name><name><surname>Vanhala</surname><given-names>R</given-names></name><etal/></person-group><article-title>Increased presynaptic dopamine function in Asperger syndrome</article-title><source>Neuroreport</source><year>2004</year><volume>15</volume><fpage>757</fpage><lpage>760</lpage><pub-id pub-id-type="pmid">15073509</pub-id></mixed-citation></ref><ref id="bib44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makkonen</surname><given-names>I</given-names></name><name><surname>Riikonen</surname><given-names>R</given-names></name><name><surname>Kokki</surname><given-names>H</given-names></name><name><surname>Airaksinen</surname><given-names>MM</given-names></name><name><surname>Kuikka</surname><given-names>JT</given-names></name></person-group><article-title>Serotonin and dopamine transporter binding in children with autism determined by SPECT</article-title><source>Dev Med Child Neurol</source><year>2008</year><volume>50</volume><fpage>593</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">18754896</pub-id></mixed-citation></ref><ref id="bib45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Sekine</surname><given-names>Y</given-names></name><name><surname>Ouchi</surname><given-names>Y</given-names></name><name><surname>Tsujii</surname><given-names>M</given-names></name><name><surname>Yoshikawa</surname><given-names>E</given-names></name><name><surname>Futatsubashi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Brain serotonin and dopamine transporter bindings in adults with high-functioning autism</article-title><source>Arch Gen Psychiatry</source><year>2010</year><volume>67</volume><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">20048223</pub-id></mixed-citation></ref><ref id="bib46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>RUPP Autism Network</collab></person-group><article-title>Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity</article-title><source>Arch Gen Psychiatry</source><year>2005</year><volume>62</volume><fpage>1266</fpage><lpage>1274</lpage><pub-id pub-id-type="pmid">16275814</pub-id></mixed-citation></ref><ref id="bib47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>C</given-names></name><name><surname>Rutter</surname><given-names>M</given-names></name><name><surname>Le Couteur</surname><given-names>A</given-names></name></person-group><article-title>Autism diagnostic interview-revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders</article-title><source>J Autism Dev Disord</source><year>1994</year><volume>24</volume><fpage>659</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">7814313</pub-id></mixed-citation></ref><ref id="bib48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faraone</surname><given-names>SV</given-names></name><name><surname>Perlis</surname><given-names>RH</given-names></name><name><surname>Doyle</surname><given-names>AE</given-names></name><name><surname>Smoller</surname><given-names>JW</given-names></name><name><surname>Goralnick</surname><given-names>JJ</given-names></name><name><surname>Holmgren</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Molecular genetics of attention-deficit/hyperactivity disorder</article-title><source>Biol Psychiatry</source><year>2005</year><volume>57</volume><fpage>1313</fpage><lpage>1323</lpage><pub-id pub-id-type="pmid">15950004</pub-id></mixed-citation></ref><ref id="bib49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wendland</surname><given-names>JR</given-names></name><name><surname>Martin</surname><given-names>BJ</given-names></name><name><surname>Kruse</surname><given-names>MR</given-names></name><name><surname>Lesch</surname><given-names>KP</given-names></name><name><surname>Murphy</surname><given-names>DL</given-names></name></person-group><article-title>Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531</article-title><source>Mol Psychiatry</source><year>2006</year><volume>11</volume><fpage>224</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">16402131</pub-id></mixed-citation></ref><ref id="bib50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>EH</given-names><suffix>Jr.</suffix></name><name><surname>Stein</surname><given-names>MA</given-names></name><name><surname>Krasowski</surname><given-names>MD</given-names></name><name><surname>Cox</surname><given-names>NJ</given-names></name><name><surname>Olkon</surname><given-names>DM</given-names></name><name><surname>Kieffer</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Association of attention-deficit disorder and the dopamine transporter gene</article-title><source>Am J Hum Genet</source><year>1995</year><volume>56</volume><fpage>993</fpage><lpage>998</lpage><pub-id pub-id-type="pmid">7717410</pub-id></mixed-citation></ref><ref id="bib51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaikh</surname><given-names>S</given-names></name><name><surname>Collier</surname><given-names>D</given-names></name><name><surname>Kerwin</surname><given-names>RW</given-names></name><name><surname>Pilowsky</surname><given-names>LS</given-names></name><name><surname>Gill</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Dopamine D4 receptor subtypes and response to clozapine</article-title><source>Lancet</source><year>1993</year><volume>341</volume><fpage>116</fpage><pub-id pub-id-type="pmid">8093383</pub-id></mixed-citation></ref><ref id="bib52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lott</surname><given-names>DC</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Cook</surname><given-names>EH</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name></person-group><article-title>Serotonin transporter genotype and acute subjective response to amphetamine</article-title><source>Am J Addict</source><year>2006</year><volume>15</volume><fpage>327</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">16966188</pub-id></mixed-citation></ref><ref id="bib53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">15297300</pub-id></mixed-citation></ref><ref id="bib54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname><given-names>WJ</given-names></name><name><surname>Sugnet</surname><given-names>CW</given-names></name><name><surname>Furey</surname><given-names>TS</given-names></name><name><surname>Roskin</surname><given-names>KM</given-names></name><name><surname>Pringle</surname><given-names>TH</given-names></name><name><surname>Zahler</surname><given-names>AM</given-names></name><etal/></person-group><article-title>The human genome browser at UCSC</article-title><source>Genome Res</source><year>2002</year><volume>12</volume><fpage>996</fpage><lpage>1006</lpage><pub-id pub-id-type="pmid">12045153</pub-id></mixed-citation></ref><ref id="bib55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbloom</surname><given-names>KR</given-names></name><name><surname>Dreszer</surname><given-names>TR</given-names></name><name><surname>Long</surname><given-names>JC</given-names></name><name><surname>Malladi</surname><given-names>VS</given-names></name><name><surname>Sloan</surname><given-names>CA</given-names></name><name><surname>Raney</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>ENCODE whole-genome data in the UCSC Genome Browser: update 2012</article-title><source>Nucleic Acids Res</source><year>2012</year><volume>40</volume><supplement>(Database issue</supplement><fpage>D912</fpage><lpage>D917</lpage><pub-id pub-id-type="pmid">22075998</pub-id></mixed-citation></ref><ref id="bib56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>LD</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name></person-group><article-title>HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants</article-title><source>Nucleic Acids Res</source><year>2012</year><volume>40</volume><supplement>(Database issue</supplement><fpage>D930</fpage><lpage>D934</lpage><pub-id pub-id-type="pmid">22064851</pub-id></mixed-citation></ref><ref id="bib57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakker</surname><given-names>PR</given-names></name><name><surname>van Harten</surname><given-names>PN</given-names></name><name><surname>van Os</surname><given-names>J</given-names></name></person-group><article-title>Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis</article-title><source>Schizophr Res</source><year>2006</year><volume>83</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">16513329</pub-id></mixed-citation></ref><ref id="bib58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnsten</surname><given-names>AF</given-names></name></person-group><article-title>Catecholamine influences on dorsolateral prefrontal cortical networks</article-title><source>Biol Psychiatry</source><year>2011</year><volume>69</volume><fpage>e89</fpage><lpage>e99</lpage><pub-id pub-id-type="pmid">21489408</pub-id></mixed-citation></ref><ref id="bib59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalley</surname><given-names>JW</given-names></name><name><surname>Cardinal</surname><given-names>RN</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name></person-group><article-title>Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates</article-title><source>Neurosci Biobehav Rev</source><year>2004</year><volume>28</volume><fpage>771</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">15555683</pub-id></mixed-citation></ref><ref id="bib60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oades</surname><given-names>RD</given-names></name><name><surname>Sadile</surname><given-names>AG</given-names></name><name><surname>Sagvolden</surname><given-names>T</given-names></name><name><surname>Viggiano</surname><given-names>D</given-names></name><name><surname>Zuddas</surname><given-names>A</given-names></name><name><surname>Devoto</surname><given-names>P</given-names></name><etal/></person-group><article-title>The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles</article-title><source>Dev Sci</source><year>2005</year><volume>8</volume><fpage>122</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">15720370</pub-id></mixed-citation></ref><ref id="bib61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purper-Ouakil</surname><given-names>D</given-names></name></person-group><article-title>[Use of psychotropic drugs in children]</article-title><source>Arch Pediatr</source><year>2008</year><volume>15</volume><fpage>1834</fpage><lpage>1836</lpage><pub-id pub-id-type="pmid">18995997</pub-id></mixed-citation></ref><ref id="bib62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>GV</given-names></name><name><surname>Goldman-Rakic</surname><given-names>PS</given-names></name></person-group><article-title>Modulation of memory fields by dopamine D1 receptors in prefrontal cortex</article-title><source>Nature</source><year>1995</year><volume>376</volume><fpage>572</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">7637804</pub-id></mixed-citation></ref><ref id="bib63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misener</surname><given-names>VL</given-names></name><name><surname>Luca</surname><given-names>P</given-names></name><name><surname>Azeke</surname><given-names>O</given-names></name><name><surname>Crosbie</surname><given-names>J</given-names></name><name><surname>Waldman</surname><given-names>I</given-names></name><name><surname>Tannock</surname><given-names>R</given-names></name><etal/></person-group><article-title>Linkage of the dopamine receptor D1 gene to attention-deficit/hyperactivity disorder</article-title><source>Mol Psychiatry</source><year>2004</year><volume>9</volume><fpage>500</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">14569274</pub-id></mixed-citation></ref><ref id="bib64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bobb</surname><given-names>AJ</given-names></name><name><surname>Addington</surname><given-names>AM</given-names></name><name><surname>Sidransky</surname><given-names>E</given-names></name><name><surname>Gornick</surname><given-names>MC</given-names></name><name><surname>Lerch</surname><given-names>JP</given-names></name><name><surname>Greenstein</surname><given-names>DK</given-names></name><etal/></person-group><article-title>Support for association between ADHD and two candidate genes: NET1 and DRD1</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2005</year><volume>134B</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">15717291</pub-id></mixed-citation></ref><ref id="bib65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bobb</surname><given-names>AJ</given-names></name><name><surname>Castellanos</surname><given-names>FX</given-names></name><name><surname>Addington</surname><given-names>AM</given-names></name><name><surname>Rapoport</surname><given-names>JL</given-names></name></person-group><article-title>Molecular genetic studies of ADHD: 1991 to 2004</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2005</year><volume>132B</volume><fpage>109</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">15700344</pub-id></mixed-citation></ref><ref id="bib66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillberg</surname><given-names>C</given-names></name><name><surname>Svennerholm</surname><given-names>L</given-names></name></person-group><article-title>CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood</article-title><source>Br J Psychiatry</source><year>1987</year><volume>151</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">2445409</pub-id></mixed-citation></ref><ref id="bib67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guiard</surname><given-names>BP</given-names></name><name><surname>El Mansari</surname><given-names>M</given-names></name><name><surname>Blier</surname><given-names>P</given-names></name></person-group><article-title>Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus ceruleus, and dorsal hippocampus</article-title><source>Mol Pharmacol</source><year>2008</year><volume>74</volume><fpage>1463</fpage><lpage>1475</lpage><pub-id pub-id-type="pmid">18703671</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>Individual parent-rated Aberrant Behavior Checklist (ABC)-hyperactivity scores during double-blind crossover trial. Top panel includes non-responders; bottom panel responders (see text for definition). Individual weekly ratings obtained at baseline and during random-order crossover weeks of methylphenidate treatment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tpj201323f1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>Genotype associations with methylphenidate clinical response rates. Positive response defined as Clinical Global Impression-Improvement (CGI-I) rating by blinded study clinician of &#x02018;much improved' or &#x02018;very much improved' and decrease in parent-rated Aberrant Behavior Checklist-Hyperactivity subscale of &#x0003e;25&#x00025; from baseline for any active drug week. <italic>n</italic>=58 subjects. <italic>P</italic>-values reflect results of &#x003c7;<sup>2</sup> tests. Panels a&#x02013;h are plots of genotype group and their respective response rates for: 2a) <italic>DRD1</italic> rs5326; 2b) <italic>DRD1</italic> rs4867798; 2c) <italic>DRD3</italic> rs6280; 2d) <italic>DRD4</italic> rs11246226; 2e) <italic>ADRA2A</italic> rs1800544; 2f) <italic>SLC6A3</italic> VNTR; 2g) <italic>SLC6A4</italic> STin2; 2h) <italic>COMT</italic> rs4680.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tpj201323f2"/></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>ABC-hyperactivity ratings and SNAP ratings in genotyped children with ASD (<italic>n</italic>=58) at entry into the double-blind phase</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><italic>Outcome measure</italic></th><th align="center" valign="top" char="." charoff="50">N</th><th align="center" valign="top" char="&#x000b1;" charoff="50"><italic>Mean (&#x000b1;s.d.)</italic></th><th align="center" valign="top" char="&#x000b1;" charoff="50"><italic>Item mean (&#x000b1;s.d.)</italic></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Parent SNAP-IV ADHD (18 items)</td><td align="char" valign="top" char="." charoff="50">58</td><td align="char" valign="top" char="&#x000b1;" charoff="50">39.1&#x000b1;7.9</td><td align="char" valign="top" char="&#x000b1;" charoff="50">2.26&#x000b1;0.43</td></tr><tr><td align="left" valign="top" charoff="50">Parent SNAP-IV ODD (8 items)</td><td align="char" valign="top" char="." charoff="50">58</td><td align="char" valign="top" char="&#x000b1;" charoff="50">9.67&#x000b1;6.17</td><td align="char" valign="top" char="&#x000b1;" charoff="50">1.21&#x000b1;0.78</td></tr><tr><td align="left" valign="top" charoff="50">Parent ABC-hyperactivity rating at baseline (16 items)</td><td align="char" valign="top" char="." charoff="50">58</td><td align="char" valign="top" char="&#x000b1;" charoff="50">33.6&#x000b1;7.43</td><td align="char" valign="top" char="&#x000b1;" charoff="50">2.09&#x000b1;0.47</td></tr><tr><td align="left" valign="top" charoff="50">Teacher SNAP-IV ADHD (18 items)</td><td align="char" valign="top" char="." charoff="50">54</td><td align="char" valign="top" char="&#x000b1;" charoff="50">35.74&#x000b1;8.23</td><td align="char" valign="top" char="&#x000b1;" charoff="50">2.05&#x000b1;0.46</td></tr><tr><td align="left" valign="top" charoff="50">Teacher SNAP-IV ODD (8 items)</td><td align="char" valign="top" char="." charoff="50">54</td><td align="char" valign="top" char="&#x000b1;" charoff="50">8.48&#x000b1;4.64</td><td align="char" valign="top" char="&#x000b1;" charoff="50">1.07&#x000b1;0.59</td></tr><tr><td align="left" valign="top" charoff="50">Teacher ABC-hyperactivity rating (16 items)</td><td align="char" valign="top" char="." charoff="50">54</td><td align="char" valign="top" char="&#x000b1;" charoff="50">31.46&#x000b1;8.68</td><td align="char" valign="top" char="&#x000b1;" charoff="50">1.94&#x000b1;0.55</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: ABC, Aberrant Behavior Checklist; ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; ODD, oppositional defiant disorder; SNAP-IV, Swanson, Nolan, and Pelham-IV.</p></fn><fn id="t1-fn2"><p>Varying sample size (<italic>N</italic>) because of missing teacher data on six subjects.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>MPH responder/non-responder number by genotypes from double-blind crossover trial</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><italic>Gene</italic></th><th align="center" valign="top" charoff="50"><italic>Variant</italic></th><th align="center" valign="top" charoff="50"><italic>Alleles</italic></th><th align="center" valign="top" charoff="50"><italic>Responder &#x00025; (</italic>n<italic>)</italic></th><th align="center" valign="top" charoff="50"><italic>Non-responder &#x00025; (</italic>n<italic>)</italic></th><th align="center" valign="top" charoff="50"><italic>Genotype &#x000d7; responder status</italic> P-<italic>value</italic></th><th align="center" valign="top" charoff="50"><italic>Dose &#x000d7; genotype</italic> P-<italic>value</italic></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">DRD1</td><td align="center" valign="top" charoff="50">rs4867798</td><td align="center" valign="top" charoff="50">C&#x0002b;</td><td align="center" valign="top" charoff="50">67&#x00025; (22/33)</td><td align="center" valign="top" charoff="50">33&#x00025; (11/33)</td><td align="center" valign="top" charoff="50">0.042</td><td align="center" valign="top" charoff="50">0.577</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">TT</td><td align="center" valign="top" charoff="50">40&#x00025; (10/25)</td><td align="center" valign="top" charoff="50">60&#x00025; (15/25)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs5326</td><td align="center" valign="top" charoff="50">T&#x0002b;</td><td align="center" valign="top" charoff="50">82&#x00025; (14/17)</td><td align="center" valign="top" charoff="50">18&#x00025; (3/17)</td><td align="center" valign="top" charoff="50">0.006</td><td align="center" valign="top" charoff="50">0.215</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">CC</td><td align="center" valign="top" charoff="50">44&#x00025; (18/41)</td><td align="center" valign="top" charoff="50">56&#x00025; (23/41)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs686</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.796</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">DRD2</td><td align="center" valign="top" charoff="50">rs6277</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs6589377</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.714</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs4938019</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.292</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs7131056</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.505</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs1800498</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.714</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs2283265</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.566</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs6275</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.148</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs1800497</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.660</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">DRD3</td><td align="center" valign="top" charoff="50">rs6280</td><td align="center" valign="top" charoff="50">Ser/Ser</td><td align="center" valign="top" charoff="50">74&#x00025; (14/19)</td><td align="center" valign="top" charoff="50">26&#x00025; (5/19)</td><td align="center" valign="top" charoff="50">0.044</td><td align="center" valign="top" charoff="50">0.569</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">(Ser9Gly)</td><td align="center" valign="top" charoff="50">Gly&#x0002b;</td><td align="center" valign="top" charoff="50">46&#x00025; (18/39)</td><td align="center" valign="top" charoff="50">54&#x00025; (21/39)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs2134655</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.696</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs9880168</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.259</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs7633291</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.404</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs167771</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.795</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs3732790</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.397</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">DRD4</td><td align="center" valign="top" charoff="50">rs11246226</td><td align="center" valign="top" charoff="50">AA</td><td align="center" valign="top" charoff="50">79&#x00025; (11/14)</td><td align="center" valign="top" charoff="50">21&#x00025; (3/14)</td><td align="center" valign="top" charoff="50">0.038</td><td align="center" valign="top" charoff="50">0.013</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">C&#x0002b;</td><td align="center" valign="top" charoff="50">48&#x00025; (21/44)</td><td align="center" valign="top" charoff="50">52&#x00025; (23/44)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs3758653</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.271</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">Exon 3 VNTR</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.810</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">DRD5</td><td align="center" valign="top" charoff="50">rs10033951</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.930</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">SLC6A3</td><td align="center" valign="top" charoff="50">3'UTR VNTR</td><td align="center" valign="top" charoff="50">10&#x0002b;</td><td align="center" valign="top" charoff="50">51&#x00025; (27/53)</td><td align="center" valign="top" charoff="50">49&#x00025; (26/53)</td><td align="center" valign="top" charoff="50">0.049</td><td align="center" valign="top" charoff="50">0.316</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">9/9</td><td align="center" valign="top" charoff="50">100&#x00025; (3/3)</td><td align="center" valign="top" charoff="50">0&#x00025; (0/3)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">SLC6A4</td><td align="center" valign="top" charoff="50">rs12150214</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.078</td><td align="center" valign="top" charoff="50">0.026</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs4251417</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.577</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs11080121</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.642</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">5HTT-LPR</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.881</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">STin2 VNTR</td><td align="center" valign="top" charoff="50">10&#x0002b;</td><td align="center" valign="top" charoff="50">67&#x00025; (22/33)</td><td align="center" valign="top" charoff="50">33&#x00025; (11/33)</td><td align="center" valign="top" charoff="50">0.041</td><td align="center" valign="top" charoff="50">0.764</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">12/12</td><td align="center" valign="top" charoff="50">39&#x00025; (9/23)</td><td align="center" valign="top" charoff="50">61&#x00025; (14/23)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">ADRA2A</td><td align="center" valign="top" charoff="50">rs1800544</td><td align="center" valign="top" charoff="50">CC</td><td align="center" valign="top" charoff="50">71&#x00025; (20/28)</td><td align="center" valign="top" charoff="50">29&#x00025; (8/28)</td><td align="center" valign="top" charoff="50">0.015</td><td align="center" valign="top" charoff="50">0.790</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">G&#x0002b;</td><td align="center" valign="top" charoff="50">40&#x00025; (12/30)</td><td align="center" valign="top" charoff="50">60&#x00025; (18/30)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs12246561</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.319</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs3750625</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.546</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">MAOA/B</td><td align="center" valign="top" charoff="50">rs1465108</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.501</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs3810709</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.416</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs3027399</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.073</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs10521432</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.308</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">rs1799836</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.191</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">COMT</td><td align="center" valign="top" charoff="50">rs4680</td><td align="center" valign="top" charoff="50">Met&#x0002b;</td><td align="center" valign="top" charoff="50">64&#x00025; (25/38)</td><td align="center" valign="top" charoff="50">36&#x00025; (13/38)</td><td align="center" valign="top" charoff="50">0.049</td><td align="center" valign="top" charoff="50">0.576</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">(Val158Met)</td><td align="center" valign="top" charoff="50">Val/Val</td><td align="center" valign="top" charoff="50">36&#x00025; (7/19)</td><td align="center" valign="top" charoff="50">63&#x00025; (12/19)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Abbreviation: MPH, methylphenidate.</p></fn><fn id="t2-fn2"><p>Shaded values indicate significant <italic>P</italic>-values.</p></fn></table-wrap-foot></table-wrap></floats-group></article>